Suppr超能文献

基于微阵列表达分析的中药筛选与评价。

Screening and evaluation of traditional Chinese medicine by microarray expression analysis.

机构信息

School of Pharmacy, East China University of Science and Technology, Shanghai 200237, PR China.

出版信息

J Ethnopharmacol. 2013 Jun 3;147(3):564-9. doi: 10.1016/j.jep.2013.03.020. Epub 2013 Apr 1.

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE

Salvia miltiorrhiza is a Chinese medicinal herb, which is widely used for the treatment of cardiovascular disorders. In this article, we investigated the effects of Salvia miltiorrhiza and its hydrophilic and lipophilic components (HCS and LCS) on human umbilical vein endothelial cells (HUVECs), and the molecular mechanism was explored by microarray gene expression profiling.

MATERIALS AND METHODS

Cell proliferation and migration were used to evaluate the angiogenic effects of HCS, LCS and total extract of Salvia miltiorrhiza (TES). Microarray technology was applied to detect the gene expression of HUVECs treated with TES, HCS and LCS. Besides, quantitative real-time PCR was used to verify the microarray results.

RESULTS

Our results showed that LCS inhibited the proliferation and migration of HUVECs, HCS promoted the proliferation and migration of HUVECs, and TES did not affect the viability of HUVECs at the concentration of 5 µg/mL. From the result of principle component analysis (PCA) of microarray data, the effect of LCS on HUVECs was significantly different from the other components. Moreover, there were more differentially expression genes in LCS group than in the other groups, which meant LCS had a strong influence on HUVECs. Compared with untreated cells, 511 significantly changed genes had been detected in LCS treated cells and 236 (approximately 46%) of them were up-regulated. The mRNA expression of IL-6 was found to be increased significantly in LCS group.

CONCLUSIONS

In Salvia miltiorrhiza, HCS and LCS had opposite effects on HUVECs. LCS showed significantly inhibitory action on HUVECs proliferation and migration. It was proposed that LCS could apply in the diseases caused by vascular anomaly hyperplasia. In the mechanism of action of LCS on HUVECs, the pathways of ErbB, MAPK, p53, oxidative phosphorylation and inflammatory response were involved.

摘要

药用植物学相关性

丹参是一种中药,广泛用于治疗心血管疾病。本文研究了丹参及其亲水性和疏水性成分(HCS 和 LCS)对人脐静脉内皮细胞(HUVEC)的影响,并通过微阵列基因表达谱探讨了其分子机制。

材料与方法

采用细胞增殖和迁移实验评价 HCS、LCS 和丹参总提取物(TES)的促血管生成作用。采用微阵列技术检测 TES、HCS 和 LCS 处理的 HUVEC 基因表达谱。此外,还采用实时定量 PCR 验证微阵列结果。

结果

我们的结果表明,LCS 抑制 HUVEC 的增殖和迁移,HCS 促进 HUVEC 的增殖和迁移,而 TES 在 5μg/mL 浓度下不影响 HUVEC 的活力。从微阵列数据主成分分析(PCA)的结果来看,LCS 对 HUVEC 的作用与其他成分明显不同。此外,LCS 组差异表达基因较多,说明 LCS 对 HUVEC 影响较大。与未处理细胞相比,LCS 处理的细胞中有 511 个显著变化的基因,其中 236 个(约 46%)上调。LCS 组的 IL-6mRNA 表达明显增加。

结论

丹参中 HCS 和 LCS 对 HUVEC 有相反的作用。LCS 对 HUVEC 的增殖和迁移有明显的抑制作用。因此,LCS 可能适用于血管异常增生引起的疾病。在 LCS 对 HUVEC 的作用机制中,涉及 ErbB、MAPK、p53、氧化磷酸化和炎症反应等途径。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验